Cargando…
Association between PD‐1 inhibitor‐related adverse events and frailty assessed by frailty index in lung cancer patients
BACKGROUND: The programmed cell death protein 1 (PD‐1) inhibitor, as one of the immune checkpoint inhibitors (ICIs), is the standard treatment for advanced lung cancer. However, immune‐related adverse events (irAEs) remain poorly understood toxicities. It is unclear whether frailty plays a role in t...
Autores principales: | Li, Jun, Zhang, Xiaolin, Zhou, Shuang, Zhou, Ying, Liu, Xinmin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166957/ https://www.ncbi.nlm.nih.gov/pubmed/36727563 http://dx.doi.org/10.1002/cam4.5669 |
Ejemplares similares
-
Automated Electronic Frailty Index–Identified Frailty Status and Associated Postsurgical Adverse Events
por: Khanna, Ashish K., et al.
Publicado: (2023) -
Optimal Frailty Dimensions for Assessing Frailty and Predicting Chemotherapy Adverse Events in Older Taiwanese Cancer Patients
por: Ho, Ya-Wen, et al.
Publicado: (2022) -
Sensory and motor correlates of frailty: dissociation between frailty phenotype and frailty index
por: Beier, Florian, et al.
Publicado: (2022) -
PREDICTING ADVERSE OUTCOMES IN ED PATIENTS USING THE CLINICAL FRAILTY SCALE AND A FRAILTY INDEX
por: Rockwood, Kenneth, et al.
Publicado: (2019) -
Longitudinal changes of frailty in 8 years: comparisons between physical frailty and frailty index
por: Hwang, An-Chun, et al.
Publicado: (2021)